Skip to main content
Premium Trial:

Request an Annual Quote

21M in New Financing Will Help Galapagos Delve Into Drug Discovery

NEW YORK, March 5 - Benelux functional genomics company Galapagos Genomics on Tuesday said it has secured a €21.4 million, or roughly $18.5 million, in a first round of private-equity financing.

UK-based Abingworth Management, Apax Partners, in France, and Burrill & Company in the US participated in the round. Other investors included NIB Capital and Crucell Holland, an existing shareholder. Both firms are based in the Netherlands.
 
"Over the past three years we have built a valuable target discovery and validation platform," Onno van de Stolpe, CEO of Galapagos, said in a statement. The new cash will allow the company to take "the next step towards drug discovery, both for internal development as well as in partnerships,," he said.

Galapagos, a joint venture between Crucell and Tibotec-Virco established in 1999, is focused on target identification and validation using its adenoviral-based PhenoSelect platform.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.